Evidence map›Paper›PMID 40355583›Full record

Trial reportScientific reports2025

Multicenter, prospective clinical trial for balloon-occluded alternative infusion of cisplatin solution and fragmented gelatin particles of transarterial chemoembolization for hepatocellular carcinoma beyond up-to-seven criteria.

Sodai Hoshiai, Naoyuki Hasegawa, Takeshi Yamada, Nobuyuki Takahashi, Kensaku Mori, Kouichi Mori, Kuniaki Fukuda, Daichi Takizawa, Bryan J Mathis, Takahito Nakajima and 1 more

Abstract readMulticenter StudyClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sodai HoshiaiDepartment of Radiology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan. hoshiai@md.tsukuba.ac.jp.
Naoyuki HasegawaDepartment of Gastroenterology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan.
Takeshi YamadaDepartment of Gastroenterology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan.
Nobuyuki TakahashiDepartment of Radiology, Tsukuba Memorial Hospital, 1187-299 Kaname, Tsukuba, Ibaraki, 300-2622, Japan.
Kensaku MoriDiagnostic Imaging Department, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-Ku, Tokyo, 135-8550, Japan.
Kouichi MoriDepartment of Radiology, Tsuchiura Kyodo General Hospital, 4-1 Ootsuno, Tsuchiura, Ibaraki, 300-0028, Japan.
Kuniaki FukudaDepartment of Gastroenterology, Kasumigaura Medical Center, 2-7-14 Takatsu, Tsuchiura, Ibaraki, 300-8585, Japan.
Daichi TakizawaDepartment of Gastroenterology, Maebashi Red Cross Hospital, 389-1 Asakura, Maebashi, Gunma, 371-0811, Japan.
Bryan J MathisDepartment of Cardiovascular Surgery, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan.
Takahito NakajimaDepartment of Radiology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan.
Toshiyuki IrieDepartment of Radiology, University of Tsukuba Hospital Mito Clinical Education and Training Center, Mito Kyodo General Hospital, 3-2-7 Miyamachi, Mito, Ibaraki, 310-0015, Japan.

Funding

JSPS KAKENHI JP22K07684
6 · The paper itself

Abstract

Transarterial chemoembolization (TACE) is considered unsuitable for hepatocellular carcinoma (HCC) that exceeds up-to-7 criteria. Balloon-occluded alternative infusion of cisplatin solution and gelatin particles of transarterial chemoembolization (BOAI-TACE) has shown promise in the treatment of HCC and preservation of liver function. This prospective, single-arm study enrolled patients with HCC beyond up-to-7 criteria from five hospitals. The primary endpoint was objective response ratio (ORR) for BOAI-TACE, according to response evaluation criteria in cancer of the Liver (RECICL), at 2 months after treatment. Eighteen patients were enrolled in this study. Fourteen patients achieved response, resulting in an ORR of 77.8% (95% confidence interval [CI] 54.3-91.5%) according to both RECICL and modified response evaluation criteria in solid tumor (mRECIST) guidelines, meeting the primary endpoint. Disease control rate was 88.9% (95% CI 66.0-98.1%). No worsening of either Child-Pugh or albumin-bilirubin (ALBI) scores was observed. No serious adverse events were recorded, indicating that BOAI-TACE retains utility even in severe HCC cases while preserving liver function.

Indexed as

Antineoplastic AgentsBalloon OcclusionCarcinoma, HepatocellularChemoembolization, TherapeuticCisplatinGelatinLiver NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedProspective StudiesTreatment OutcomeAntineoplastic AgentsCisplatinGelatinHepatocellular carcinomaLiver functionTransarterial chemoembolization

Identifiers

PMID40355583
PMCPMC12069695

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.